First nonsteroidal treatment approved for patients six years of age and older with DMD regardless of genetic mutation now available in the U.S.
ITF also announces the launch of ITF ARC (Access, Resources and Care) patient services program to bring suite of support and educational resources to patients and their families
Read the Full Press Release HERE
The post ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy appeared first on CureDuchenne.